109 studies found for:    "Anal cancer"
Show Display Options
Rank Status Study
21 Recruiting Vorinostat in Combination With Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection
Conditions: HIV Infection;   Recurrent Anal Cancer;   Recurrent Breast Cancer;   Recurrent Esophageal Cancer;   Recurrent Gastric Cancer;   Recurrent Metastatic Squamous Neck Cancer With Occult Primary;   Recurrent Non-small Cell Lung Cancer;   Recurrent Ovarian Epithelial Cancer;   Recurrent Salivary Gland Cancer;   Recurrent Squamous Cell Carcinoma of the Hypopharynx;   Recurrent Squamous Cell Carcinoma of the Larynx;   Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity;   Recurrent Squamous Cell Carcinoma of the Nasopharynx;   Recurrent Squamous Cell Carcinoma of the Oropharynx;   Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Recurrent Verrucous Carcinoma of the Larynx;   Recurrent Verrucous Carcinoma of the Oral Cavity;   Salivary Gland Squamous Cell Carcinoma;   Stage IV Anal Cancer;   Stage IV Breast Cancer;   Stage IV Esophageal Cancer;   Stage IV Gastric Cancer;   Stage IV Non-small Cell Lung Cancer;   Stage IV Ovarian Epithelial Cancer;   Stage IV Salivary Gland Cancer;   Stage IV Squamous Cell Carcinoma of the Hypopharynx;   Stage IV Squamous Cell Carcinoma of the Larynx;   Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IV Squamous Cell Carcinoma of the Nasopharynx;   Stage IV Squamous Cell Carcinoma of the Oropharynx;   Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Stage IV Verrucous Carcinoma of the Larynx;   Stage IV Verrucous Carcinoma of the Oral Cavity;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: vorinostat;   Other: diagnostic laboratory biomarker analysis;   Other: pharmacological study;   Drug: carboplatin;   Drug: paclitaxel
22 Completed 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)
Conditions: Advanced Adult Primary Liver Cancer;   Carcinoma of the Appendix;   Estrogen Receptor-negative Breast Cancer;   Extensive Stage Small Cell Lung Cancer;   Gastrointestinal Stromal Tumor;   HER2-negative Breast Cancer;   Metastatic Gastrointestinal Carcinoid Tumor;   Ovarian Sarcoma;   Ovarian Stromal Cancer;   Progesterone Receptor-negative Breast Cancer;   Recurrent Adenoid Cystic Carcinoma of the Oral Cavity;   Recurrent Adult Primary Liver Cancer;   Recurrent Anal Cancer;   Recurrent Basal Cell Carcinoma of the Lip;   Recurrent Borderline Ovarian Surface Epithelial-stromal Tumor;   Recurrent Breast Cancer;   Recurrent Cervical Cancer;   Recurrent Colon Cancer;   Recurrent Endometrial Carcinoma;   Recurrent Esophageal Cancer;   Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity;   Recurrent Extrahepatic Bile Duct Cancer;   Recurrent Gallbladder Cancer;   Recurrent Gastric Cancer;   Recurrent Gastrointestinal Carcinoid Tumor;   Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity;   Recurrent Lymphoepithelioma of the Nasopharynx;   Recurrent Lymphoepithelioma of the Oropharynx;   Recurrent Metastatic Squamous Neck Cancer With Occult Primary;   Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity;   Recurrent Mucoepidermoid Carcinoma of the Oral Cavity;   Recurrent Non-small Cell Lung Cancer;   Recurrent Ovarian Epithelial Cancer;   Recurrent Ovarian Germ Cell Tumor;   Recurrent Pancreatic Cancer;   Recurrent Prostate Cancer;   Recurrent Rectal Cancer;   Recurrent Salivary Gland Cancer;   Recurrent Small Cell Lung Cancer;   Recurrent Small Intestine Cancer;   Recurrent Squamous Cell Carcinoma of the Hypopharynx;   Recurrent Squamous Cell Carcinoma of the Larynx;   Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity;   Recurrent Squamous Cell Carcinoma of the Nasopharynx;   Recurrent Squamous Cell Carcinoma of the Oropharynx;   Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Recurrent Verrucous Carcinoma of the Larynx;   Recurrent Verrucous Carcinoma of the Oral Cavity;   Small Intestine Adenocarcinoma;   Small Intestine Leiomyosarcoma;   Small Intestine Lymphoma;   Stage IV Adenoid Cystic Carcinoma of the Oral Cavity;   Stage IV Anal Cancer;   Stage IV Basal Cell Carcinoma of the Lip;   Stage IV Borderline Ovarian Surface Epithelial-stromal Tumor;   Stage IV Breast Cancer;   Stage IV Colon Cancer;   Stage IV Endometrial Carcinoma;   Stage IV Esophageal Cancer;   Stage IV Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity;   Stage IV Gastric Cancer;   Stage IV Inverted Papilloma of the Paranasal Sinus and Nasal Cavity;   Stage IV Lymphoepithelioma of the Nasopharynx;   Stage IV Lymphoepithelioma of the Oropharynx;   Stage IV Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity;   Stage IV Mucoepidermoid Carcinoma of the Oral Cavity;   Stage IV Non-small Cell Lung Cancer;   Stage IV Ovarian Epithelial Cancer;   Stage IV Ovarian Germ Cell Tumor;   Stage IV Pancreatic Cancer;   Stage IV Prostate Cancer;   Stage IV Rectal Cancer;   Stage IV Salivary Gland Cancer;   Stage IV Squamous Cell Carcinoma of the Hypopharynx;   Stage IV Squamous Cell Carcinoma of the Larynx;   Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IV Squamous Cell Carcinoma of the Nasopharynx;   Stage IV Squamous Cell Carcinoma of the Oropharynx;   Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Stage IV Verrucous Carcinoma of the Larynx;   Stage IV Verrucous Carcinoma of the Oral Cavity;   Stage IVA Cervical Cancer;   Stage IVB Cervical Cancer;   Triple-negative Breast Cancer;   Unresectable Extrahepatic Bile Duct Cancer;   Unresectable Gallbladder Cancer;   Unspecified Adult Solid Tumor, Protocol Specific;   Untreated Metastatic Squamous Neck Cancer With Occult Primary
Interventions: Drug: 7-hydroxystaurosporine;   Drug: irinotecan hydrochloride;   Other: diagnostic laboratory biomarker analysis
23 Active, not recruiting Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer
Conditions: Adenocarcinoma of the Colon;   Adenocarcinoma of the Rectum;   Advanced Adult Primary Liver Cancer;   Carcinoma of the Appendix;   Gastrointestinal Stromal Tumor;   Metastatic Gastrointestinal Carcinoid Tumor;   Metastatic Squamous Neck Cancer With Occult Primary;   Recurrent Adenoid Cystic Carcinoma of the Oral Cavity;   Recurrent Adult Primary Liver Cancer;   Recurrent Anal Cancer;   Recurrent Basal Cell Carcinoma of the Lip;   Recurrent Colon Cancer;   Recurrent Esophageal Cancer;   Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity;   Recurrent Extrahepatic Bile Duct Cancer;   Recurrent Gallbladder Cancer;   Recurrent Gastric Cancer;   Recurrent Gastrointestinal Carcinoid Tumor;   Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity;   Recurrent Lymphoepithelioma of the Nasopharynx;   Recurrent Lymphoepithelioma of the Oropharynx;   Recurrent Metastatic Squamous Neck Cancer With Occult Primary;   Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity;   Recurrent Mucoepidermoid Carcinoma of the Oral Cavity;   Recurrent Non-small Cell Lung Cancer;   Recurrent Pancreatic Cancer;   Recurrent Rectal Cancer;   Recurrent Salivary Gland Cancer;   Recurrent Small Intestine Cancer;   Recurrent Squamous Cell Carcinoma of the Hypopharynx;   Recurrent Squamous Cell Carcinoma of the Larynx;   Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity;   Recurrent Squamous Cell Carcinoma of the Nasopharynx;   Recurrent Squamous Cell Carcinoma of the Oropharynx;   Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Recurrent Verrucous Carcinoma of the Larynx;   Recurrent Verrucous Carcinoma of the Oral Cavity;   Small Intestine Adenocarcinoma;   Small Intestine Leiomyosarcoma;   Small Intestine Lymphoma;   Stage IV Adenoid Cystic Carcinoma of the Oral Cavity;   Stage IV Anal Cancer;   Stage IV Basal Cell Carcinoma of the Lip;   Stage IV Colon Cancer;   Stage IV Esophageal Cancer;   Stage IV Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity;   Stage IV Gastric Cancer;   Stage IV Inverted Papilloma of the Paranasal Sinus and Nasal Cavity;   Stage IV Lymphoepithelioma of the Nasopharynx;   Stage IV Lymphoepithelioma of the Oropharynx;   Stage IV Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity;   Stage IV Mucoepidermoid Carcinoma of the Oral Cavity;   Stage IV Non-small Cell Lung Cancer;   Stage IV Pancreatic Cancer;   Stage IV Rectal Cancer;   Stage IV Salivary Gland Cancer;   Stage IV Squamous Cell Carcinoma of the Hypopharynx;   Stage IV Squamous Cell Carcinoma of the Larynx;   Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IV Squamous Cell Carcinoma of the Nasopharynx;   Stage IV Squamous Cell Carcinoma of the Oropharynx;   Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Stage IV Verrucous Carcinoma of the Larynx;   Stage IV Verrucous Carcinoma of the Oral Cavity;   Tongue Cancer;   Unresectable Extrahepatic Bile Duct Cancer;   Unresectable Gallbladder Cancer
Interventions: Drug: cetuximab;   Drug: erlotinib hydrochloride;   Other: laboratory biomarker analysis
24 Completed Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction
Conditions: Adult Anaplastic Astrocytoma;   Adult Anaplastic Ependymoma;   Adult Anaplastic Oligodendroglioma;   Adult Brain Stem Glioma;   Adult Diffuse Astrocytoma;   Adult Ependymoblastoma;   Adult Giant Cell Glioblastoma;   Adult Glioblastoma;   Adult Gliosarcoma;   Adult Mixed Glioma;   Adult Myxopapillary Ependymoma;   Adult Oligodendroglioma;   Adult Pilocytic Astrocytoma;   Adult Primary Hepatocellular Carcinoma;   Adult Subependymoma;   Advanced Adult Primary Liver Cancer;   Advanced Malignant Mesothelioma;   Male Breast Cancer;   Recurrent Adenoid Cystic Carcinoma of the Oral Cavity;   Recurrent Adult Brain Tumor;   Recurrent Adult Primary Liver Cancer;   Recurrent Anal Cancer;   Recurrent Basal Cell Carcinoma of the Lip;   Recurrent Bladder Cancer;   Recurrent Breast Cancer;   Recurrent Cervical Cancer;   Recurrent Colon Cancer;   Recurrent Esophageal Cancer;   Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity;   Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity;   Recurrent Lymphoepithelioma of the Nasopharynx;   Recurrent Lymphoepithelioma of the Oropharynx;   Recurrent Malignant Mesothelioma;   Recurrent Metastatic Squamous Neck Cancer With Occult Primary;   Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity;   Recurrent Mucoepidermoid Carcinoma of the Oral Cavity;   Recurrent Non-small Cell Lung Cancer;   Recurrent Ovarian Epithelial Cancer;   Recurrent Pancreatic Cancer;   Recurrent Prostate Cancer;   Recurrent Rectal Cancer;   Recurrent Salivary Gland Cancer;   Recurrent Squamous Cell Carcinoma of the Hypopharynx;   Recurrent Squamous Cell Carcinoma of the Larynx;   Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity;   Recurrent Squamous Cell Carcinoma of the Nasopharynx;   Recurrent Squamous Cell Carcinoma of the Oropharynx;   Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Recurrent Verrucous Carcinoma of the Larynx;   Recurrent Verrucous Carcinoma of the Oral Cavity;   Stage II Esophageal Cancer;   Stage II Pancreatic Cancer;   Stage III Esophageal Cancer;   Stage III Pancreatic Cancer;   Stage IIIB Non-small Cell Lung Cancer;   Stage IV Adenoid Cystic Carcinoma of the Oral Cavity;   Stage IV Anal Cancer;   Stage IV Basal Cell Carcinoma of the Lip;   Stage IV Bladder Cancer;   Stage IV Breast Cancer;   Stage IV Colon Cancer;   Stage IV Esophageal Cancer;   Stage IV Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity;   Stage IV Inverted Papilloma of the Paranasal Sinus and Nasal Cavity;   Stage IV Lymphoepithelioma of the Nasopharynx;   Stage IV Lymphoepithelioma of the Oropharynx;   Stage IV Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity;   Stage IV Mucoepidermoid Carcinoma of the Oral Cavity;   Stage IV Non-small Cell Lung Cancer;   Stage IV Ovarian Epithelial Cancer;   Stage IV Pancreatic Cancer;   Stage IV Prostate Cancer;   Stage IV Rectal Cancer;   Stage IV Salivary Gland Cancer;   Stage IV Squamous Cell Carcinoma of the Hypopharynx;   Stage IV Squamous Cell Carcinoma of the Larynx;   Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IV Squamous Cell Carcinoma of the Nasopharynx;   Stage IV Squamous Cell Carcinoma of the Oropharynx;   Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Stage IV Verrucous Carcinoma of the Larynx;   Stage IV Verrucous Carcinoma of the Oral Cavity;   Stage IVA Cervical Cancer;   Stage IVB Cervical Cancer;   Unspecified Adult Solid Tumor, Protocol Specific;   Untreated Metastatic Squamous Neck Cancer With Occult Primary
Interventions: Drug: erlotinib hydrochloride;   Other: laboratory biomarker analysis
25 Recruiting International Multicentre Study in Advanced Anal Cancer Comparing Cisplatin Plus 5 FU vs Carboplatin Plus Weekly Paclitaxel
Condition: Squamous Cell Carcinoma of the Anus
Interventions: Drug: Cisplatin;   Drug: 5-Fluorouracil (5-FU);   Drug: Carboplatin;   Drug: Paclitaxel
26 Recruiting Topical MTS-01 for Dermatitis During Radiation and Chemotherapy for Anal Cancer
Condition: Anal Cancer
Interventions: Drug: Tempol;   Drug: 5-Fluorouracil;   Drug: Mitomycin-C;   Procedure: Radiation Therapy
27 Unknown  Molecular Genetic and Pathological Studies of Anal Tumors
Conditions: Rectal Cancer;   Colon Cancer;   Colonic Neoplasms;   Anal Cancer
Intervention: Other: genetic analysis
28 Unknown  Low-Fiber Diet or High-Fiber Diet in Preventing Bowel Side Effects in Patients Undergoing Radiation Therapy for Gynecological Cancer, Bladder Cancer, Colorectal Cancer, or Anal Cancer
Conditions: Anal Cancer;   Bladder Cancer;   Cervical Cancer;   Colorectal Cancer;   Fallopian Tube Cancer;   Gastrointestinal Complications;   Ovarian Cancer;   Radiation Toxicity;   Sarcoma
Interventions: Dietary Supplement: dietary intervention;   Other: laboratory biomarker analysis;   Procedure: gastrointestinal complications management/prevention;   Procedure: management of therapy complications;   Radiation: selective external radiation therapy
29 Completed Infrared Coagulation in Preventing Anal Cancer in Patients With HIV Who Have Anal Neoplasia
Conditions: Anal Cancer;   Precancerous Condition
Interventions: Procedure: infrared photocoagulation therapy;   Device: Infrared Coagulator
30 Completed SGN-00101 in Preventing Anal Cancer in Patients With HIV Who Have Anal Neoplasia
Condition: Anal Cancer
Intervention: Biological: HspE7
31 Active, not recruiting Infrared Coagulator Ablation or Observation in Preventing Anal Cancer in HIV-Positive Patients With Anal Neoplasia
Conditions: Anal Cancer;   Neoplasm of Uncertain Malignant Potential;   Nonneoplastic Condition;   Precancerous Condition
Interventions: Other: clinical observation;   Procedure: infrared photocoagulation therapy
32 Not yet recruiting Study to Determine the Feasibility of Sentinel Node Biopsy in Patients With Anal Cancer
Condition: Squamous Cell Carcinoma of the Anus
Intervention: Procedure: Sentinel lymph node biopsy
33 Completed Image Fusion PET, CT and 3D-ultrasound Examinations
Condition: Anal Cancer
Intervention:
34 Recruiting Anal HPV Tests in Screening for Cell Changes in the Anus in Patients With HIV
Conditions: Anal Cancer;   HIV Infection;   Human Papilloma Virus Infection
Interventions: Procedure: comparison of screening methods;   Other: laboratory biomarker analysis;   Other: questionnaire administration;   Procedure: quality-of-life assessment
35 Completed Hybrid Capture 2 Human Papiloma Virus (HPV) High-Risk Anal DNA Test
Conditions: Anal Canal HPV Infection Diagnosis;   Anal Dysplasia Diagnosis;   Anal Cancer
Intervention: Device: HC2 collection kit with a swab or brush
36 Terminated QOL & Functional Outcomes After Combined Modality Tx for Anal CA: Comparison of Conventional vs IMRT
Condition: Anal Cancer
Intervention:
37 Completed Octreotide in Preventing or Reducing Diarrhea in Patients Receiving Chemoradiotherapy for Anal or Rectal Cancer
Conditions: Anal Cancer;   Colorectal Cancer;   Drug/Agent Toxicity by Tissue/Organ;   Radiation Enteritis
Intervention: Drug: octreotide acetate
38 Completed Vaccine Therapy in Treating Patients With Advanced or Recurrent Cancer
Conditions: Anal Cancer;   Cervical Cancer;   Esophageal Cancer;   Head and Neck Cancer;   Penile Cancer;   Vulvar Cancer
Interventions: Biological: human papillomavirus 16 E7 peptide;   Biological: synthetic human papillomavirus 16 E6 peptide
39 Completed Interleukin-12 in Treating Patients With Cancer in the Abdomen
Conditions: Anal Cancer;   Colorectal Cancer;   Gallbladder Cancer;   Gastric Cancer;   Pancreatic Cancer
Intervention: Biological: Recombinant Interleukin-12
40 Active, not recruiting Irinotecan, Fluorouracil, and Leucovorin in Treating Patients With Advanced Gastrointestinal Cancer
Conditions: Anal Cancer;   Carcinoma of the Appendix;   Colorectal Cancer;   Esophageal Cancer;   Extrahepatic Bile Duct Cancer;   Gallbladder Cancer;   Gastric Cancer;   Gastrointestinal Carcinoid Tumor;   Gastrointestinal Stromal Tumor;   Liver Cancer;   Pancreatic Cancer;   Small Intestine Cancer
Interventions: Drug: fluorouracil;   Drug: irinotecan hydrochloride;   Drug: leucovorin calcium;   Other: pharmacogenomic studies;   Other: pharmacological study

Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results
Indicates status has not been verified in more than two years